TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Update

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) saw a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 26,400 shares, a decline of 78.5% from the March 31st total of 123,000 shares. Based on an average trading volume of 49,800 shares, the short-interest ratio is currently 0.5 days. Approximately 0.2% of the company's stock are sold short.

Insider Buying and Selling

In other TriSalus Life Sciences news, CFO James Emmett Young acquired 6,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Wednesday, February 5th. The stock was bought at an average cost of $5.65 per share, for a total transaction of $33,900.00. Following the acquisition, the chief financial officer now owns 30,000 shares of the company's stock, valued at $169,500. This represents a 25.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 32.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in TriSalus Life Sciences by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 204,137 shares of the company's stock valued at $1,023,000 after acquiring an additional 3,710 shares during the last quarter. Bank of America Corp DE increased its stake in TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company's stock worth $894,000 after buying an additional 178,298 shares during the period. Bridgeway Capital Management LLC lifted its holdings in TriSalus Life Sciences by 333.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company's stock valued at $326,000 after buying an additional 50,000 shares in the last quarter. Northern Trust Corp boosted its position in TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock valued at $161,000 after buying an additional 5,936 shares during the period. Finally, Connective Capital Management LLC bought a new position in TriSalus Life Sciences in the 4th quarter worth about $140,000. Institutional investors own 2.58% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TLSI shares. Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They set a "buy" rating and a $10.00 price objective for the company. Roth Mkm reissued a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, March 28th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $11.56.

TriSalus Life Sciences Price Performance

Shares of TLSI stock traded down $0.01 on Friday, hitting $5.09. 43,163 shares of the stock traded hands, compared to its average volume of 41,942. The firm has a market cap of $164.10 million, a price-to-earnings ratio of -2.04 and a beta of 0.49. The firm has a 50 day simple moving average of $5.49 and a two-hundred day simple moving average of $4.92. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.24.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.35) earnings per share for the quarter, meeting the consensus estimate of ($0.35). The company had revenue of $8.26 million for the quarter, compared to analysts' expectations of $8.12 million. Sell-side analysts forecast that TriSalus Life Sciences will post -1.55 EPS for the current year.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.